Genzyme — Ilex Oncology — Merger or Acquisition (May 2004)
32 slides from Genzyme's merger presentation, May 4, 2004
Slide 1: Genzyme May 2004
Slide 2: Forward-Looking Statements
Forward-Looking Statements These presentations contain fomardlecking statement, including without imitation statements regarding sthe potental business combination bebueen Genzyme and LEX Induding expected ting, benefis and EPS impact 200% financial guidance “projected plans and Sing for product dev
Slide 3: Registration statement and proxy solicitation notice
genzynne On April 5, 2004, Genzyme filed with the U.S. Securities and Exchange Commission a registration statement on Form $-4 relating to the merger. This presentation is not a substitute for the prospectus/proxy statement, a preliminary form of which is included in the registration statement. Inve
Slide 4: Leading positions in well-defined markets
e@ Leading positions in well-defined markets @ Arisk-balanced approach - diversified, global, vertical e@ Strong momentum in 2003, into 2004 — expanded marketed product portfolio e@ Long-term growth drivers in place — advancing, multi-stage pipeline
Slide 5: Agenda: Company Overview
enda @ Company Overview rowth
Slide 6: Our Focus Remains Consistent
ur Foc RemaifigiGonsistent We seek frontiers Serious diseases — unmet needs We develop and deliver breakthrough therapies and services - Significant a improvement to patients’ lives Patient-focused Standard of care products Technologically neutral Sustainably creating shareholder value
Slide 7: Therapeutic Areas
Therapeutic Areas Transplant & Oneolagy/ Ustinparilies Immune Disease [i Endocrinology *Cerezyme® *Renagel® *symvisc® “Thyrogen® *Fabrazyme® Sevelamer-CKD *Carticel® ‘Lymphoglobulin® Cancer programs *aldurazyme® Renal fibrosis Symvisc It RDP.68 Myozyme® PKD Dx-88 Niemann Pick Anti-TGFB antibodies MS
Slide 8: WW Reported Revenues: Q1 2004 / YE 2003
WW Reported Revemiies: Q1 2004 / YE 2003 genzyme ai Full Year in millions, unaudited Q1'04 Q1'03 2003 2002 3] Renal $ 83 $ 59 $ 282 $ 187 Therapeutics 255 189 865 675 24 Transplant 36 “ 44 - | Biosurgery 48 - 119 - St ®) Diagnostics’ a) Plagnost 52 47 191 173 Other 16 16 79 62 Total Revenues $491 $3
Slide 9: Genzyme Corporation 2004 Guidance
Genzyme Corporatian 2004 Guidance notine fF ILEXAMPA High Cerezyme s7m $m SRA. (658) (675) Fabrazymme m0 85 rap at ee meget 52 anorTizarion (103) (108) other 2 F 2 = nverinterest ol 4 Total Therapeutios, seo 1080 NET OTHER 4118) Renal 2538 Trymoglobulin 20109 TAX RATE 2% 3% ther Products 0 452008 GA
Slide 10: Multi-Stage Growth Plan
@ Multi-Stage Growth Plan e@ |ILEX merger @ Genzyme mar
Slide 11: Executing Multi-Stage Growth Plan
Executing Multi-Stage Growth Plan genzyme Other $ Millions Products $3,000 2Other LSDs Synvisc® $2,500 ‘Renagel® $2,000 $1,500 Diagnostics). Cerezyme® Genetics $1,000 $500 92 93 94 95 96 OF 98 99 OO O01 O2 03 O4E OSE Notes: Excludes Renagel revenues of $19.51 in 1999 and $8.0M in 2000, which were re
Slide 12: ILEX Oncology Profile
ILEX Oncology Pigstile @ Focus on development of oncology drugs — Strong franchise with growing product (CAMPATH®) — Promising pipeline with two late-stage products — First class clinical development organization - Strong scientific resources @ Locations in Texas, Massachusetts, Switzerland, England
Slide 13: Transaction Overview
Transaction Overmmew ® Stock for stock transaction — $26.00/share, collar of $59.88 (0.4342) to $46.58 (0.5582) — ILEX approximately 39M shares outstanding —- Exchange ratio fixed at time of closing e@ Expected EPS impact to Genzyme - Excluding amortization, modestly dilutive in near-term - Accretiv
Slide 14: ILEX Pipeline
ILEX Pipeline CAMPATH - CLL clofarabine — Ped ALL/AML et CAMPATH - MS ————___—__—_- ILX-651 - NSCLC a ll ILX-651 - Melanoma —— APOMINE SS CAMPATH - NHL —— clofarabine - Solid NM3 Preclinical Phase! Phase ll Phase Ill Registration Marketed
Slide 15: Genzyme Oncology, Combined with ILEX
Genzyme Oncology, Combined with JIEEX Mid-Stage Development + TAPs + TEM Ab + Fusion Vaccine + ILX651 + PRL3 + Polyamines + DENSPM + TEM Sm + TGF-B Ab Pivotal * Regulatory! : ; Sales and Development Reimbursement (Seta sete sail bes) Marketing + Clofarabine + 2NDAs + Campathin 2007 > 12 MSLs -Existi
Slide 16: Genzyme: Acquisition of IMPATH
Genzyme: Acquisition of IMPATH Cancer Testing Business g @ $215 million cash purchase of Physician Services and Analytical Services business unit @ Acquisition complete May, 2004 e@ IMPATH — Leader in oncology testing area — Sites in Los Angeles (~270 employees), Phoenix (~95 employees) and New York
Slide 17: Multi-Stage Growth Plan
@ Multi-Stage Growth Plan @ ILEX ge e@ Genzyme marketed products
Slide 18: Cerezyme for Gaucher Disease
Cerezyme® (imiglucerase) f@iGaucher Disease Our Flagship Product WW Revenues ($M) $739 $619 Maintaining strong market position — Ongoing product enhancements — EU label expanded = Enhancing patient services $93 — Committed to worldwide availability $203 92 93 94 95 98 97 98 99 O0 Mf O2 03 Ot-04
Slide 19: Fabrazyme for Fabry Disease
Fabrazyme® (agalsidase beta) for Fabry Disease An Important Growl Driver WW Revenues ($M) $38.1 ®@ Developing global market © Strong international performance — Rapid growth continues — 31 countries — Japan launch H1'04 e U.S. launch progressing well $23 — Broad label, co-selling with Renal tear a4'
Slide 20: Aldurazyme revenues
WW Revenues ($M) < $7.3 $6.7 @ Approved in U.S. and EU in April and June, 2003 — broad label indication — solid start to both launches $3.4 — ~220 patients on therapy WW. (~85% are commercial) ® Clinical base developing $1.1 — global market development | | — children <5 yrs - data YE'04 (E) = care p
Slide 21: Thyrogen: Expanding Indications
Thyrogen® (thyrotropin alfalfor injection) Expanding Indications WW Revenues ($M) { $43 @ Marketed in U.S. since 1997 — new standard of care for thyroid cancer testing ‘ — consistent growth H e Future growth H $14 — expanded indications include goiter and ablation | pale — clinical trials ongoing in
Slide 22: Renagel (Sevelamer HCl)
Renageél®(Sevelamer hy A Long-term Gro More than just a phosphate binder ® Solid global revenue growth @ Increasing medical recognition — key part of ESRD treatment — unique lipid lowering effect National Kidney Foundation new guidelines (K/DOQI) — first-line therapy — limit use of calcium, benefiti
Slide 23: Renagel: Global Growth Opportunity
Renage Global Growth Oppoflunity WW Kidney Dialysis Patients: ~1.2 M United States Europe Rest of World ~320,000 patients ~250,000 patients ~630,000 patients ~AT% Renagel® share ~$181 ~$76 l L | 2003 Revenue ($M) ote: fnludes Chugei hull supaty ae yates Source: Fresenius Annual Report and Genzyme es
Slide 24: Synvisc revenues
WW Revenues ($M) from Synvisc® © Vertically integrated 5 technology platform (HA) b2 e Early stage US/EU markets Expanding indications @ Next generation under development 2001 2002 2003 J End-User Sales [MM Genzyme Revenues
Slide 25: Thymoglobulin: A Product Leader in Transplant
Thymoglobulin® (Anti-thymocyte Globulin (Rabbit)) A Product Leader itg@iiransplant WW Revenues ($M)* © Standard of care in acute H xn | A renal transplant rejection — investigating use in i $59.1 induction, BMT e Future growth — increased marketing efforts ex-U.S LJ — exploit broad E.U. label — expa
Slide 26: Next Wave of Growth Drivers
Next Wave of Growati Drivers ® 82 clinical studies currently ongoing Advancing pipeline: — 25in Phase 1 or 1/2 — 17 in Phase 2 or 2/3 ~ Tin Phase 3 25 in Phase 4 (postmarketing) 8 in Registry/Survey Protocol 2 0 0 © om OD Om O2 me OME Oe 2005 and Beyond
Slide 27: In the Clinic: Pompe Disease
In the Clinic The Unmet Need: Pompe Disease @ Severe muscle degeneration = 5,000 to 10,000 estimated patients worldwide — no available treatment Status @ Largest R&D initiative Fast-track regulatory strategy Past trials yielded encouraging results Two new studies initiated in 2003 Primary end point
Slide 28: Link to searchable text of slide shown above
Link to searchable text of slide shown above
Slide 29: Agenda: Strategy and Outlook
Slide 30: 2004 — Continuing to Execute
2004 — Continuing te Execute e@ Expand franchise products - LSDs — Renagel® e@ Broaden use of commercial products — Thyrogen®— ablation, goiter — Synvisc®— hip, shoulder, ankle — Thymoglobulin® — induction, BMT @ Advance our pipeline — Myozyme®, anti-TGFB antibodies, DX-88, Tolevamer, MS-small molec
Slide 31: Leading positions in well-defined markets
v Leading positions in well-defined markets vo Arisk-balanced approach — diversified, global, vertical vo Long-term growth drivers in place — pipeline advancing to plan vy Strong momentum into 2004 — building on 2003 achievements — 2/16/04 ’04 revenue guidance: — $1.9B - $2.0B — 2/16/04 ‘04 (E) EPS
Slide 32: Searchable text section
Searchable text section of graphics shown above May , 2004 The presentation includes certain non-GAAP financial measures that involve adjustments to GAAP figures. Genzyme believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understan